OSR Holdings Inc. (NASDAQ: OSRH) stated it will not pursue a reverse stock split as it approaches its Nasdaq minimum bid compliance deadline, according to a company statement from Chief Executive Officer Kuk Hyoun "Peter" Hwang.

The company filed its Preliminary Proxy Statement on Schedule PRE 14A with the U.S. Securities and Exchange Commission on May 11, 2026, which did not include a proposal authorizing a reverse stock split. Hwang said management evaluated and rejected this option, stating the company intends to achieve Nasdaq compliance through operational execution rather than financial restructuring.

OSR Holdings recently executed definitive agreements with BCM Europe AG for the global exclusive license of VXM01, representing up to $815 million in potential milestone payments for the company's oncology platform. The deal was announced on April 29, 2026.

The company's subsidiary Woori IO is advancing its non-invasive glucose monitoring platform through a collaboration with Samsung Electronics and is conducting discussions under non-disclosure agreement with Sinopharm.

OSR Holdings operates as a healthcare holding company focused on biomedical innovations through subsidiaries engaged in immuno-oncology, regenerative biologics, and medical device technologies. The company is based in Bellevue, Washington.

The statement acknowledged that while there can be no assurance regarding timing or outcomes, the company remains engaged with advisors and Nasdaq regarding compliance restoration.